Shalika Bohingamu

Dec 5, 2024 | bmccancer.biomedcentral.com | BeiGene USA |San Mateo |Shalika Bohingamu

The incidence, prevalence, and mortality rates of ESCC and GEJC were calculated based on the cancer registry data and the specific Australian mid-year population size. Subgroup analysis by sex was conducted for the corresponding incidence, prevalence, and mortality rate. The incidence trends in the next 20 years were predicted using the coefficients identified from least square simple linear regression constructed from the 2009 to 2018 data [17].